ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.9621
-0.06%
Brent Oil
83.705
0.09%
Bitcoin
59,439.98
0.54%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aldeyra Therapeutics Inc (ALDX)

  7. Aldeyra Therapeutics Inc (ALDX) Noticias

ALDX Aldeyra Therapeutics Inc

4.21
0.01 (0.24%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Aldeyra Therapeutics Inc ALDX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01 0.24% 4.21 15:33:49
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.23 4.085 4.235 4.21 4.20
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202406:00BWAldeyra Therapeutics Highlights Recent Preclinical Data in..
18/4/202406:00BWAldeyra Therapeutics to Host Research & Development Day on..
28/3/202406:00BWAldeyra Therapeutics Announces Clinical Development Plan for..
07/3/202415:54EDGAR2Form S-3 - Registration statement under Securities Act of..
07/3/202415:48EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/3/202415:40EDGAR2Form S-8 POS - Securities to be offered to employees in..
07/3/202415:06EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/2/202406:00BWAldeyra Therapeutics to Participate in the Oppenheimer 34th..
29/1/202416:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
04/1/202406:00EDGAR2Form 8-K - Current report
04/1/202406:00BWAldeyra Therapeutics Provides Clinical and Regulatory Update..
21/12/202315:06EDGAR2Form 8-K - Current report
19/12/202306:05EDGAR2Form 8-K - Current report
19/12/202306:00BWAldeyra Therapeutics Announces Statistically and Clinically..
18/12/202315:01BWAldeyra Therapeutics Schedules Conference Call and Webcast..
28/11/202306:16EDGAR2Form 8-K - Current report
27/11/202315:07BWAldeyra Therapeutics Receives Complete Response Letter from..
03/11/202315:43EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/11/202315:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202306:09EDGAR2Form 8-K - Current report
01/11/202306:05BWAldeyra Therapeutics Enters into Exclusive Option Agreement..
16/10/202307:00EDGAR2Form 8-K - Current report
27/9/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
26/9/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
19/9/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
12/9/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
11/9/202316:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
24/8/202315:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
16/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
11/8/202304:45PRNUSALDX SHAREHOLDER ALERT: Jakubowitz Law Reminds Aldeyra..
09/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
04/8/202304:45PRNUSALDX SHAREHOLDER ALERT: Jakubowitz Law Reminds Aldeyra..
03/8/202315:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/7/202306:00BWAldeyra Therapeutics to Participate in SVB Securities..
05/7/202316:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202316:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202315:07EDGAR2Form 8-K - Current report
29/6/202315:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202306:01EDGAR2Form 8-K - Current report
29/6/202306:00BWAldeyra Therapeutics Announces Improvement from Baseline in..
28/6/202315:01BWAldeyra Therapeutics Schedules Conference Call and Webcast..
27/6/202306:00BWAldeyra Therapeutics Announces Statistically Significant..
26/6/202315:01BWAldeyra Therapeutics Schedules Conference Call and Webcast..
23/6/202306:00BWAldeyra Therapeutics to Join the Russell 2000® and Russell..
21/6/202308:34BWAldeyra Therapeutics Provides Regulatory Update on ADX-2191
15/6/202306:00BWAldeyra Therapeutics Announces Achievement of Statistical..
14/6/202315:01BWAldeyra Therapeutics Schedules Conference Call and Webcast..

Su Consulta Reciente

NASDAQ
ALDX
Aldeyra Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados